• Event Type: Q4 FY26 Earnings Conference Call held on May 28, 2026 to discuss Audited Financial Results for the quarter and year ended March 31, 2026.
  • Date and Time: The call was held on May 28, 2026 (specific time not mentioned in transcript).
  • Purpose: Discussion of quarterly results, business performance, regulatory updates, and strategic outlook.
  • Management Participants:
  • Dr. Satish Wagh – Executive Chairman and Whole-Time Director
  • Dr. Saloni Wagh – Managing Director
  • Mr. Krishna Raghunathan – Chief Financial Officer
  • Moderator: Ms. Sneha Salian – EY Investor Relations
  • Availability of Materials: The investor presentation and financial results were available on the company website and stock exchanges. The transcript along with the audio recording was made available on the company website and exchanges.
  • Compliance Language: The company noted that anything said on the call reflecting future outlook must be viewed in conjunction with risks the company faces. The audio is copyright material of Supriya Lifescience Limited and cannot be copied or rebroadcast without written consent.
  • Financial Period Discussed: Q4 FY26 and Full Year FY26 results (ended March 31, 2026).
  • Forward-Looking Statements: Management reiterated guidance of approximately 20% annual revenue growth and EBITDA margin of 33% to 35%. The trajectory towards INR1,000 crores revenue milestone by FY27 remains on track.
  • Strategic Themes: Focus on expanding regulated markets, strengthening competitive edge through backward integration, regulatory expertise, and broad portfolio. Planned launches of 3-4 products annually across therapeutic segments including anesthetics, antibiotics, antianxiety, vitamins and ADHD.

Financial Highlights from Call

Q4 FY26 Performance:

  • Revenue from operations: INR277 crores (vs INR184 crores in Q4 FY25, +50% YoY)
  • EBITDA: INR98 crores (vs INR68 crores in Q4 FY25, +44% YoY)
  • EBITDA margin: 35.5%
  • PAT: INR74 crores (vs INR50 crores in Q4 FY25)
  • PAT margin: 26.8%

Full Year FY26 Performance:

  • Revenue: INR828 crores (vs INR696 crores in FY25, +19% YoY)
  • EBITDA: INR294 crores (vs INR261 crores in FY25, +13% YoY)
  • EBITDA margin: 35.5% (surpassing guided range of 33-35%)
  • PAT: INR209 crores
  • PAT margin: 25.3%

Operational Highlights:

  • Export segment contributed 82% of FY26 revenues
  • Europe delivered healthy growth with 40% share during the year
  • Backward integration reached 76% in FY26
  • Capex for FY26: INR152 crores (largely driven by Ambernath facility)
  • Working capital: 170 days in FY26 (expected 170-180 days going forward)
  • Effective tax rate: 25.17% for full year

Regulatory Update:

  • Lote facility received USFDA Establishment Inspection Report (EIR) with Voluntary Action Indicated classification following surprise inspection in February 2026
  • Inspection resulted in only one minor observation which was proactively addressed

Product Updates:

  • Cardiovascular product launched in Q3 FY26 began contributing in Q4 FY26
  • ADHD product launched with strong demand from LATAM and Europe
  • Liquid anaesthetic product commercialized during the year
  • Contrast media product expected to launch in H2 FY27
  • For FY27: Plan to strengthen anesthetics and ADHD portfolios with ~2 new launches in each segment

Capacity Expansion:

  • Received all clearances for Patalganga land with phased development beginning with Phase 1 groundbreaking in FY27
  • Phase 1 capex earmarked at INR200 crores
  • Project includes two API/advanced intermediate blocks and two formulation blocks
  • F block at Lote plant to add 150-200 KL capacity with INR40-50 crores capex

Additional Business Updates:

  • DSM contract contributed INR30-35 crores in FY26, expected peak of INR60 crores in FY27
  • Annual maintenance shutdown scheduled for August in older blocks A&D
  • GLP-1 product development in discussion phase with Indian generic company (2+ years for revenue)
  • Novel semaglutide tablet formulation patent filed with different binding agent

Additional Notes Section

  • The transcript was made available on the company's website at https://www.supriyalifescience.com/ir-financial.php
  • The document contains detailed financial figures and operational metrics from the earnings call
  • The transcript includes full Q&A session with analysts covering various aspects of business performance and strategy